Drugs / DOTAP:Chol-TUSC2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01455389 | Feb 2014 → Oct 2016 | lung cancer | Genprex, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2017-04-02 | Genprex, Inc. | Results Genprex reports New Pre-Clinical Data Showing Strong Anti-Tumor Effect of TUSC2 in Combination with PD-1 Checkpoint Blockade in Lung Cancer genprex.com ↗
The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlated with prolonged survival in mice. |
| 2017-01-06 | Genprex, Inc. | Results Genprex Announces Positive Interim Data from Phase II Clinical Trial of Oncoprex™ for Late Stage Non-Small Cell Lung Cancer genprex.com ↗
The clinical trial results in nine (9) patients evaluable to date show an overall disease control rate (stable disease, partial response or complete response) of 78%. |
| 2012-04-26 | Genprex, Inc. | Results Clinical Trial Highlights Positive Oncoprex Results in Lung Cancer Patients genprex.com ↗
A clinical trial has demonstrated that Oncoprex® (TUSC2 nanoparticles) can be safely administered in advanced lung cancer patients to halt cancer or shrink primary and metastatic tumors in some patients. |
| 2012-04-02 | Genprex, Inc. | Results Oncoprex Shows Synergistic Tumor Suppression in Combination with AKT Inhibitor MK2206 genprex.com ↗
The treatment with the combination of Oncoprex and MK2206 resulted in tumor volume reduction of greater than 2.5 times the tumor reduction achieved with MK2206 alone. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-04-02 | Genprex, Inc. | Genprex reports New Pre-Clinical Data Showing Strong Anti-Tumor Effect of TUSC2 in Combination with PD-1 Checkpoint Blockade in Lung Cancer genprex.com ↗ |
| 2017-01-06 | Genprex, Inc. | Genprex Announces Positive Interim Data from Phase II Clinical Trial of Oncoprex™ for Late Stage Non-Small Cell Lung Cancer genprex.com ↗ |
| 2012-04-26 | Genprex, Inc. | Clinical Trial Highlights Positive Oncoprex Results in Lung Cancer Patients genprex.com ↗ |
| 2012-04-02 | Genprex, Inc. | Oncoprex Shows Synergistic Tumor Suppression in Combination with AKT Inhibitor MK2206 genprex.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DOTAP:Chol-TUSC2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01455389 ↗ |
| Known as | FUS1 | “DOTAP:Chol-TUSC2 (previously FUS1) is a drug that helps transfer a gene called TUSC2 into cancer cells.” NCT01455389 ↗ |
| Route | Intravenous | “DOTAP:Chol-TUSC2 is given by vein as an infusion over 25-35 minutes” NCT01455389 ↗ |